The global peptide API market is experiencing unprecedented growth, driven by the surging demand for peptide-based therapeutics across multiple disease areas. According to recent market analysis, the global CDMO Service for Peptide APIs market was valued at US$ 3,986 million in 2025 and is anticipated to reach US$ 13,186 million by 2032, at a remarkable CAGR of 18.6%[reference:12]. This explosive growth reflects the increasing complexity of peptide drug development and the growing reliance on specialized contract manufacturing organizations.
The peptide therapeutics contract API manufacturing market has grown strongly in recent years, expanding from $2.89 billion in 2025 to an expected $3.1 billion in 2026 at a CAGR of 7.3%[reference:13]. This growth is projected to continue, with the market reaching $4.11 billion by 2030[reference:14]. Key factors driving this expansion include the limited number of specialized peptide API manufacturers, growing demand for peptide therapeutics, and increasing preclinical and clinical trials[reference:15].
North America currently leads the peptide API market, driven by robust pharmaceutical R&D investment and a strong presence of major biopharmaceutical companies. The region's market share exceeds 50%, with Europe following at approximately 33% and China at 9%[reference:16]. However, the Asia-Pacific region, particularly China and India, is emerging as a significant growth hub due to lower manufacturing costs, expanding manufacturing capabilities, and favorable regulatory environments. The GCC region is also using healthcare diversification and life-science localization programs to reduce import dependence and attract pharmaceutical manufacturing[reference:17].
Major trends shaping the peptide API market include the expansion of CMO capabilities for peptide API production, rising investment in advanced peptide synthesis technologies, growth of personalized medicine and biologics, and increasing outsourcing by small and mid-size pharma companies[reference:18]. The adoption of digital manufacturing and AI-based process optimization is also gaining traction[reference:19]. Key companies operating in this space include Thermo Fisher Scientific, Lonza Group, WuXi AppTec, Cambrex, ChemPartner, GenScript Biotech, and Bachem Group[reference:20].
The rising prevalence of diabetes is a primary driver of growth in the peptide therapeutics contract API manufacturing market[reference:21]. With over 500 million adults living with diabetes worldwide, the demand for GLP-1 receptor agonists like semaglutide and liraglutide, as well as next-generation insulin analogs, continues to surge. This unprecedented demand is putting immense pressure on global supply chains, leading to shortages and forcing manufacturers to expand their capacities rapidly. CDMOs are investing billions in new facilities and continuous manufacturing technologies to keep pace with this growing demand.